Pelgifatamab corixetan

柯立派妥单抗

Report date: 2025/09/24 17:55:50

Base Information

Drug NamePelgifatamab corixetan

Drug Alias NamePSMA targeted thorium-227 conjugatePSMA TTC227Th-PSMA TTCBAY-2315497

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomFinland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Develop Information

Active CompaniesBayer AG

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A